𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer

✍ Scribed by Yuan Yao; Angela M. H. Brodie; Nancy E. Davidson; Thomas W. Kensler; Qun Zhou

Publisher
Springer US
Year
2010
Tongue
English
Weight
399 KB
Volume
124
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Activation of the Nrf2–ARE signaling pat
Activation of the Nrf2–ARE signaling pathway: a promising strategy in cancer prevention
✍ Aldo Giudice; Maurizio Montella πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 193 KB πŸ‘ 2 views

A major protective mechanism against oxidizing substances capable of damaging DNA integrity and initiating carcinogenesis is the induction of phase II detoxification and antioxidant enzymes by chemopreventive agents. A key finding in the field of chemoprevention has been the discovery that the induc

Bidirectional interactions between the e
Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells
✍ Thomas W. Grunt; Miguel Saceda; Mary Beth Martin; Ruth Lupu; Evelyn Dittrich; Ge πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 French βš– 993 KB

The responsiveness of estrogen receptor (ER)-positive breast cancer to endocrine therapy is frequently reduced in cells over-expressing c-erbB-2. Stimulation of ER suppresses c-erbB-2, indicating that estrogen controls the activity of c-erbB-2. Heregulin (HRG) has been described to bind to c-erbB-3/